Moderna Stock Rises 6.8% on CDC Panel's Flu Vaccine Recommendation
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
modernamrna
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Shares of Moderna Inc. (MRNA) advanced 6.8% on Wednesday, June 18, 2026, following a key regulatory recommendation for the company's investigational mRNA influenza vaccine. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to include the Moderna flu shot in its recommended vaccine schedule for the 2026-2027 season. This endorsement is a significant regulatory milestone for Moderna's first commercial product beyond its COVID-19 franchise, potentially unlocking a large and stable seasonal market. The Wall Street Journal reported the committee's decision, which is typically adopted by the full CDC director.
Moderna's core revenue has declined from its pandemic-era peak, placing intense pressure on the company to diversify its product portfolio. The last major regulatory catalyst for Moderna's non-COVID pipeline was the FDA approval of its RSV vaccine in late 2025, which contributed to a 14% single-day stock gain. The current macro backdrop for biotech is characterized by elevated interest rates, which have pressured valuations for pre-revenue companies, making near-term commercial catalysts like this one especially critical.
The immediate catalyst was the unanimous vote by the CDC's independent vaccine advisory panel. This committee reviews clinical data on safety, efficacy, and public health need before making schedule recommendations. A positive vote signals to healthcare providers and payers that the vaccine is a viable option for the upcoming flu season, which typically begins in October. The recommendation directly precedes the final CDC director sign-off and the critical manufacturing and distribution ramp for fall vaccinations.
Moderna's stock closed at $152.40 on June 18, a gain of $9.68 from the previous day's close of $142.72. Trading volume reached 28.5 million shares, more than double its 30-day average of 12.1 million. The company's market capitalization increased by approximately $3.7 billion in the single session, pushing it above $59 billion.
The potential market opportunity is substantial. The U.S. seasonal influenza vaccine market is estimated at $7 billion annually. Moderna's vaccine demonstrated a superior efficacy profile in Phase 3 trials, showing a relative vaccine efficacy of 53.7% against symptomatic flu compared to 45.3% for standard-dose egg-based quadrivalent vaccines. This performance compares to the biotech sector benchmark, the SPDR S&P Biotech ETF (XBI), which was flat on the day. A key data point shows Moderna's year-to-date performance turning positive, now up 4% versus a decline of 8% prior to this news.
| Metric | Before Recommendation (June 17 Close) | After Recommendation (June 18 Close) | Change |
|---|---|---|---|
| Share Price | $142.72 | $152.40 | +6.8% |
| 30-Day Avg Volume | 12.1M | 28.5M | +135% |
| Market Cap | ~$55.3B | ~$59.0B | +$3.7B |
The recommendation creates clear second-order effects across the vaccine competitive landscape. Primary beneficiaries include Moderna's manufacturing partners and lipid nanoparticle suppliers, such as Catalent (CTLT) and Avid Bioservices (CDMO), which could see increased contract revenue. Companies with adjuvant technology used in traditional flu shots, like Dynavax (DVAX), may face incremental long-term pressure as mRNA platforms gain share. The broader mRNA sector, including BioNTech (BNTX), which is developing its own flu candidate, benefits from validated regulatory pathways for non-COVID applications.
A key limitation is that a recommendation does not guarantee commercial success. Uptake depends on pricing, distribution contracts, and public acceptance, areas where incumbent players like Sanofi (SNY) and GSK (GSK) have deep relationships. Sanofi's Fluzone franchise generated over $3 billion in 2025 sales. The risk for Moderna is that initial market penetration may be slow despite superior efficacy data.
Positioning data indicates short covering likely amplified the day's move. Moderna had a short interest of approximately 8% of float entering the week. The flow is moving into other mid-cap biotechs with late-stage infectious disease pipelines, as investors anticipate similar binary catalysts. Options activity showed heavy buying of short-dated calls, suggesting traders expect volatility to persist through the final CDC decision.
The next specific catalyst is the final ratification by the CDC Director, expected within the next two weeks. Following that, the Advisory Committee on Immunization Practices will issue its formal voting rationale and detailed clinical guidance in early July. Moderna is scheduled to report Q2 2026 earnings on July 24, where management will provide initial manufacturing and launch commentary for the flu vaccine.
Key price levels for Moderna stock include immediate resistance at the 200-day moving average near $158, which it has not sustained above since January. Support is established at the June 17 gap-up level of $142. For the sector, watch the XBI ETF's resistance at the $95 level, a break above which could signal renewed institutional interest in biotech. The 10-year Treasury yield, currently at 4.2%, remains a headwind; a sustained move below 4.0% would improve valuation models for long-duration biotech assets.
The recommendation allows Moderna to compete in the U.S. seasonal flu market for the first time. Analyst consensus estimates project 2027 flu vaccine sales between $800 million and $1.2 billion for Moderna, assuming a 10-15% market share in its launch season. This revenue would be high-margin and recurring, significantly diversifying the company away from its cyclical COVID-19 booster business. Peak sales projections for the mRNA flu vaccine exceed $3 billion annually if it gains broad adoption over several seasons.
Moderna's vaccine, mRNA-1010, is manufactured using cell-based technology, avoiding potential adaptation changes that can occur in egg-based production and potentially improving the match to circulating strains. The Phase 3 trial demonstrated statistically superior efficacy against both influenza A and B strains compared to standard egg-based quadrivalent vaccines. Traditional shots require months of lead time for egg-based production, while mRNA platform manufacturing is potentially faster and more scalable for responding to strain shifts.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.